Cipla has received final USFDA approval for Medroxyprogesterone injectable for prevention of pregnancy in the markets of America. The injection Medroxyprogesterone injectable 150mg/million is a generic version of Pfizer’s Depo-Provera and has an approximate market potential of around USD 159 million for the 12-month period ending November 2018. The injection is indicated only for the prevention of pregnancy.
Company Profile : Cipla Ltd
Leave a Reply